Elevated low-density lipoprotein

Similar documents
( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

In 2001, the National Cholesterol Education Program

Nearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III

Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.

High ( 50%) Restrictions mg 20-40mg PA; TS ⱡ 15 ⱡ

Fibrates. Spotlight on. Fibric acid derivatives (fibrates) have been used. When should I prescribe fibrates? In this article: Andrew s visit

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia

Management of Post-transplant hyperlipidemia

Low HDL and Diabetic Dyslipidemia

nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck

Achieving Lipid Goals: 2008 Update. Laura Hansen, Pharm.D. Associate Professor, University of Colorado School of Pharmacy

STATIN UTILIZATION MANAGEMENT CRITERIA

MOLINA HEALTHCARE OF CALIFORNIA

Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin

HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016

Lipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD

How would you manage Ms. Gold

The American Diabetes Association estimates

Hyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH

Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients

Clinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date:

Diabetic Dyslipidemia

Learning Objectives. Patient Case

ATP IV: Predicting Guideline Updates

Lipid Panel Management Refresher Course for the Family Physician

Rosuvastatin: An Effective Lipid Lowering Drug against Hypercholesterolemia

Review of guidelines for management of dyslipidemia in diabetic patients

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient

Medical evidence suggests that

See Important Reminder at the end of this policy for important regulatory and legal information.

When it comes to the FIELD study, what is...is

Treating Lipids for Prevention of CAD in Women: Matching Therapy to Risk

STATINS FOR PAD Long - term prognosis

Introduction. Objective. Critical Questions Addressed

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.

Cholesterol Management Roy Gandolfi, MD

The leading cause of death in the United States is coronary

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Original paper. Abstract. Abdullah S. Asia 1*, Al-Mahdi A. Modar 2, Hadi M. Ali 3

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center

Landmark Clinical Trials.

Periodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice

Disclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines

Pharmacy Drug Class Review

How to Reduce Residual Risk in Primary Prevention

Statins ARE Enough For The Prevention of CVD! Professor Kausik Ray Imperial College London, UK

Clinical Policy: Ezetimibe (Zetia) Reference Number: CP.PMN.78 Effective Date: Last Review Date: 02.19

Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist

The TNT Trial Is It Time to Shift Our Goals in Clinical

New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors

It is the policy of health plans affiliated with PA Health & Wellness that Vytorin is medically necessary when the following criteria are met:

Diabetes Mellitus: A Cardiovascular Disease

Clinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:

Cholesterol Medicines New & Old: What to Use When

hyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER

Decline in CV-Mortality

Thai people. Large epidemiology studies in ischemic stroke have shown a modest association of elevated total

B. Patient has not reached the percentage reduction goal with statin therapy

Hyperlipidemia. Intern Immersion Block 2015

Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)

See Important Reminder at the end of this policy for important regulatory and legal information.

Long-Term Complications of Diabetes Mellitus Macrovascular Complication

Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals

... CPE/CNE QUIZ... CPE/CNE QUESTIONS

Conflicts of interest. What's the Skinny on the Lipid Guidelines? Key Differences. Are you applying the new ACC/AHA Lipid guidelines in your practice?

Clinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date:

Imaging Biomarkers: utilisation for the purposes of registration. EMEA-EFPIA Workshop on Biomarkers 15 December 2006

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Prospective Natural-History Study of Coronary Atherosclerosis

Elements for a Public Summary

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.

The Cardiovascular Institute Mount Sinai School of Medicine, New York

Supplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction

CVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure

JAMA. 2011;305(24): Nora A. Kalagi, MSc

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

Drug Class Review on HMG-CoA Reductase Inhibitors (Statins)

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.

Learning Objectives. Cholesterol and Lipids in Kids: It s a Matter of the Heart. Is Atherosclerosis a Pediatric Disease?

Acute Coronary Syndromes (ACS)

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010

Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction

Coronary heart disease (CHD) has. Clearfield The National Cholesterol Education Program Adult Treatment Panel III guidelines

High ( 50%) Restrictions mg 20-40mg Simvastatin (Zocor) 10mg 20-40mg $1.66 Pravastatin (Pravachol) mg $6.

In May 2001, the National Cholesterol. Effective Management of Patients With Dyslipidemia REPORT. Robert J. Lipsy, PharmD

Elevated Triglycerides Increase the Risk of CHD at All Levels of LDL-C Incidence of CHD Events According to Serum LDL-C and TG Concentration*

International Journal of Research and Development in Pharmacy and Life Sciences. Research Article

Treating dyslipidemia

Management of Lipid Levels and Cardiovascular Disease in HIV-Infected Individuals: Just Give Them a Statin?

Placebo-Controlled Statin Trials

The New ACC/AHA Cholesterol Guideline: A Significant Change with Significant Implications

Transcription:

A for Simvastatin and Gemfibrozil Molly Haselden, PharmD, BCPS; Thomas Worrall, PharmD, BCPS; and Dorothy Jenrette, PharmD, BCPS Eliminating gemfibrozil from a statin-containing regimen may be safe and effective for patients with low triglyceride levels. Dr. Haselden is a clinical pharmacist at the Medical University of South Carolina. Dr. Worrall is an ambulatory care clinical pharmacy specialist and Dr. Jenrette is a pharmacoeconomics and patient safety clinical pharmacy specialist, both at the Ralph H. Johnson VAMC in Charleston, South Carolina. Elevated low-density lipoprotein cholesterol (LDL-C) is a major risk factor for the development of coronary artery disease (CAD). For the past decade, lowering LDL-C has been the main focus in the treatment of dyslipidemia. 1-3 Significant evidence also exists that hypertriglyceridemia is related to complications, including pancreatitis, and may also be independently linked to cardiovascular risk. 4,5 Current treatment guidelines, published by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III), establish LDL-C reduction as the primary goal and triglyceride (TG) reduction as the secondary goal. If TG levels are significantly elevated (> 500 mg/dl), then TG becomes the primary goal due to increased risk of pancreatitis. 3 Simvastatin, a 3-hydroxy-3- methylglutaryl-coenzyme (HMG- CoA) reductase inhibitor, has long been the drug of choice in the VA system for the treatment of dyslipidemia, despite its risks, which include myalgias, myopathy, and rhabdomyolysis. 6 Incidence of true statin-induced myopathy or rhabdomyolysis is very low, estimated to occur in < 1% of high-dose simvastatin users; the benefits of statin use are often thought to outweigh the risks of therapy. 6,7 In the Helsinki Heart Study and the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT), gemfibrozil reduced TG concentrations by 20% to 50%. Gemfibrozil was shown to be useful in both the primary and secondary prevention of CAD and demonstrated mortality reduction in patients with CAD. 8,9 The combination of gemfibrozil with simvastatin has been discouraged due to the increased risk of muscle-related complications; however, in practice, the medications are often prescribed concomitantly. A pharmacokinetic study reported that gemfibrozil increased the measured area under the curve concentration of simvastatin 2-fold, likely the reason that rates of myopathy and rhabdomyolysis are 6 times greater when simvastatin is used in combination with gemfibrozil. 10 In June 2011, the FDA released new recommendations on the use of simvastatin, which included a dose limit of 40 mg (previously the maximum simvastatin dose was 80 mg) and new drug combination contraindications. 11 These recommendations were made in light of the SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine) trial, a large, randomized, placebo-controlled trial that revealed a significantly higher rate of myopathy and rhabdomyolysis with simvastatin than had other previous studies. 12 Medications cited to increase risk of simvastatin-induced muscle injury included gemfibrozil, and combination therapy is now considered a contraindicated treatment option. 10-13 In August 2011, the Pharmacy and Therapeutics (P&T) Committee at the Ralph H. Johnson VA Medical Center in Charleston, South Carolina, reviewed the FDA warning and approved an automatic conversion protocol to be applied to patients prescribed both gemfibrozil and simvastatin. First, the primary goal of therapy (either TG or LDL-C reduction) was determined. TG reduction was considered the primary goal if patients had a history of TG level of > 500 mg/dl or TG-induced pancreatitis; LDL-C was the primary goal in all other patients. Once the goal of therapy was determined, options for intervention included discontinuation of gemfibrozil, statin dose escalation, and/or addition of niacin or fish oil. In patients whose TG concentration met NCEP goal < 150 mg/dl, gemfibrozil was discontinued. Statin dose was escalated if needed for further LDL-C reduction. Per P&T recommendations, 22 FEDERAL PRACTITIONER JULY 2014

CONVERSION ALGORITHM Patients prescribed BOTH simvastatin and gemfibrozil: 1. Determine primary goal: TG (if TG > 500 or history of pancreatitis) LDL-C (goal based on Framingham risk score) 2. Primary goal LDL-C reduction a : LDL-C Action Suggested Action L DL-C at goal & TG 150 mg/dl L DL-C at goal & 151 < TG 250 mg/dl L DL-C at goal & 251 < TG 500 mg/dl L DL-C elevated from goal Continue to encourage TLC. b A dd fish oil 2 g/d. Titrate up to 4 g/d if clinically indicated. A dd Slo-Niacin Tablets 500 mg qhs, titrated to 1,500 mg qhs as tolerated. I ncrease simvastatin dose (do not exceed 40 mg qhs) or consider rosuvastatin 10 mg/d if simvastatin 40 mg daily has been reached. 3. Primary goal TG reduction: Continue gemfibrozil LDL-C at goal Starting dose Simvastatin 80 mg Simvastatin 40 mg Simvastatin 20 mg Simvastatin 10 mg Simvastatin 5 mg Conversion Rosuvastatin 10 mg Pravastatin 80 mg Pravastatin 40 mg Pravastatin 20 mg Pravastatin 10 mg LDL-C not at goal Starting dose Simvastatin 80 mg Simvastatin 40 mg Simvastatin 20 mg Simvastatin 10 mg Simvastatin 5 mg Conversion Rosuvastatin 10-20 mg c Rosuvastatin 5 mg Rosuvastatin 5 mg Rosuvastatin 2.5 mg Rosuvastatin 2.5 mg 4. LDL-C or TGs at goal after treatment with combination maximum dose rosuvastatin and gemfibrozil à discontinue gemfibrozil, titrate rosuvastatin to LDL-C goal, and add fenofibrate for TG control. This is a LAST LINE option if patient has failed all other therapies 5. Inform patient of medication changes using simvastatin/gemfibrozil combination letter template. 6. A follow-up lipid panel (and BMP if changing statin) is recommended but not required 6 to 12 weeks after the intervention. a Fenofibrate has proven efficacy in lowering TGs; however, it lacks large scale morbidity and/or mortality outcomes data; therefore, we cannot recommend the substitution of fenofibrate for gemfibrozil at this time. b TLC: Limit saturated fat < 7% of calories, cholesterol < 200 mg/d; if TG > 500: consider very low fat diet ( 15% total calories from fat); consider increased viscous (soluble) fiber (10-25 g/d) and plant stanols/sterols (2g/d); Weight management (5%-10% reduction); Increased physical activity (150 minutes vigorous exercise weekly). c Maximum dose rosuvastatin 10 mg when used in combination with gemfibrozil. BMP = bone morphogenic protein-2; LDL-C = low-density lipoprotein cholesterol; TLC = Therapeutic Lifestyle Changes; TGs = triglycerides; qhs = every night. Figure 1. Pharmacy and Therapeutics Committee Approved Conversion Algorithm for Patients Prescribed Both Gemfibrozil and Simvastatin. JULY 2014 FEDERAL PRACTITIONER 23

Figure 2. Patient Inclusion/Exclusion Criteria. a clinical pharmacist evaluated each patient, made an intervention based on the P&T approved protocol, and sent a letter, which described the intervention and the reason for the action, to each patient. This study evaluated the outcome of the P&T committeeapproved automatic conversion protocol in subgroups of patients prescribed simvastatin and gemfibrozil with a TG serum concentration 150 mg/dl at baseline (Figure 1). METHODS A retrospective chart review was conducted on all patients who had prescriptions for gemfibrozil and simvastatin, prescribed in the 52 weeks before August 15, 2011; patient records were reviewed between September 1, 2011, and April 30, 2012. Patients were included for study analysis if they underwent a P&T committee-approved conversion algorithm between September 1, 2011, and December 31, 2011, were aged 18 to 88 years, and their most recent 151 patients received prescriptions for simvastatin and gemfibrozil in 2011 62 patients excluded from analysis 32 missing laboratory data 20 with history of TG > 500 mg/dl 9 off-protocol medication changes 1 nonfasting lipid panel 81 patients: LDL-C & TG at goal at baseline Gemfibrozil discontinued Statin dose maintained 89 patients included in primary analysis 8 patients: TG at goal, but LDL-C above goal at baseline Gemfibrozil discontinued Statin dose increased TG measurement was 150 mg/dl. Only those patients who had a fasting lipid panel documented in the 56 weeks preceding the study intervention and who returned for a follow-up lipid panel within 6 to 24 weeks following the intervention were included in the study analysis. Patients were excluded from the analysis if they received prescriptions for simvastatin or gemfibrozil from pharmacies outside the VA system, if their cholesterol medications were adjusted during the observation period outside of the initial intervention, if they had any lifetime history of TG > 500 mg/dl or pancreatitis, or if the subjects were incarcerated or pregnant at any time during the study period. Relevant data were collected, using the VistA (Veterans Health Information Systems and Technology Architecture) and CPRS medical record documentation systems. Patient demographic data, including age, gender, treatment indication, past medical history, adverse drug reaction history, and prescription history were collected for analysis of the study population baseline characteristics. In addition, pertinent laboratory data were examined, including lipid parameters (total cholesterol [TC]; LDL-C; high-density lipoprotein cholesterol [HDL-C]; and TG) and liver function (LF) markers (aspartate aminotransferase [AST]/alanine aminotransferase [ALT]), both before and after the intervention. Patient charts were manually reviewed at follow-up for any adverse events (AEs) attributed to the cholesterol medications. The primary endpoints included the average change from baseline in lipid parameters, including TC, LDL-C, HDL-C, and TG in each group. Secondary endpoints included descriptions of any safety concerns or AEs. The study was approved on December 15, 2011, by the Medical University of South Carolina internal review board and the VA research and development committee. Statistical analysis was completed, using the paired Student t test for continuous data, and a descriptive analysis was performed for AEs. RESULTS Initial patient retrieval included 151 patients who had received prescriptions for gemfibrozil and simvastatin during 2010-2011 and who also had a TG level of 150 mg/ dl obtained in the previous year. Of these patients, 32 patients were missing laboratory data, 20 patients had a lifetime history of a TG level of > 500 mg/dl or pancreatitis, 9 patients had off protocol medication changes, and 1 patient had a nonfasting lipid panel. A total of 62 patients were excluded from the final analysis (Figure 2). Eighty-nine patients were included in the primary analysis; 8 of 24 FEDERAL PRACTITIONER JULY 2014

those patients were meeting their TG goal but had an LDL-C elevated from goal at baseline, and 81 patients were meeting both their TG and LDL-C goals at baseline. The baseline demographics were reflective of a typical VA population: 99% male, average age 67.3 years, 38% white and 10% African American (52% did not disclose a racial identification). The primary efficacy goal of change in average lipid parameters after intervention was assessed at 6 to 24 weeks postintervention. Eighty-one patients who met both TG and LDL-C goals at baseline were evaluated (Table 1, Figure 3). Average TC, LDL-C, HDL-C, and AST were not significantly different before and after intervention. There was a statistically significant difference in the average TG levels preintervention and postintervention (107.5 mg/dl vs 159.5 mg/dl; P <.001). Average ALT was significantly higher in the postintervention group (19.6 vs 27; P <.001). In patients with TGs 150 mg/dl who did not meet the LDL-C goal at baseline, there was also a statistically significant difference in average TG levels pre- and postintervention (107.6 mg/dl vs 156.1 mg/dl; P =.01). Average LDL-C did not significantly change pre- and postintervention (119.6 mg/dl vs 119.1 mg/dl; P =.82), nor did TC, HDL-C, or AST/ALT (Table 2, Figure 4). There were no AEs reported in the 6 to 24 weeks following the intervention that could have been attributed to the cholesterol medications. In addition, there were no new diagnoses of pancreatitis entered in the patient s medical records in the follow-up period. Of note, the range of TG levels after discontinuation of gemfibrozil was 38 mg/dl to 341 mg/dl. After the intervention, 17 of 89 patients Table 1. Average Lipid Parameters Pre- and ; LDL-C Meeting Goal at Baseline (n = 81) Preintervention (95% CI) (19%) had TG levels of > 200 mg/dl; however, only 1 of 89 patients had a TG level of > 300 mg/dl. No patients had a measured TG level of > 500 mg/dl after the intervention. DISCUSSION There was a statistically significant increase in TG concentrations in both groups after discontinuation of gemfibrozil, regardless of change in statin dose. However, the clinical significance of this increase is debatable. The NCEP ATP III guidelines define a TG goal of < 150 mg/dl, and in this study, the average TG level after discontinuation of gemfibrozil was 159.5 mg/dl (95% CI) P Value TC 143.8 (± 6.5) 147.5 (± 6.3) =. 45 LDL-C 81.2 (± 5.3) 75.0 (± 4.5) =. 1 TGs 107.5 (± 4.8) 159.5 (± 14.4) <.001 HDL-C 41.2 (± 2.5) 40.9 (± 2.7) =.91 AST 21.7 (± 1.4) 23.7 (± 1.9) =.15 ALT 19.6 (± 1.9) 27.0 (± 3.9) =.003 ALT = alanine aminotransferase; AST = aspartate aminotransferase; CI = confidence interval; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TGs = triglycerides. Figure 3. Results: Patients Meeting TG and LDL-C Goals at Baseline (n = 81). 200 150 100 50 0 Preintervention TC LDL-C TGs HDL-C AST ALT ALT = alanine aminotransferase; AST = aspartate aminotransferase; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TC = total cholesterol; TGs = triglycerides. in the group meeting LDL-C goal and 156.1 mg/dl in the group not meeting LDL-C goal. Following this strict definition, patients did not maintain TG control after the study intervention. Nevertheless, 80% of patients moved from the normal category (TG < 150 mg/dl) preintervention to the borderline high category (TG 150-200 mg/dl) postintervention per ATP III definitions. 3 The importance of TGs as an independent marker for cardiovascular risk has been debated for decades. Data from the Copenhagen City Heart Study indicated that plasma TG levels were significantly associ- JULY 2014 FEDERAL PRACTITIONER 25

Table 2. Average Lipid Parameters Pre- and ; LDL-C Not Meeting Goal at Baseline (n = 8) Pre-intervention (95% CI) ated with increased risk of nonhemorrhagic ischemic events. The relative risk (RR) of ischemic stroke was increased 1.12 (95% confidence interval [CI], 1.07 1.16) for every 88.6 mg/dl increase in TGs in that population. 14 A meta-analysis of 17 prospective studies of Western subjects found TGs to be an independent risk factor for cardiovascular disease (CVD) endpoints; RR was 1.14 in men (95% CI, 1.05 1.28) and 1.37 in women (95% CI) P Value TC 185.8 (± 21.8) 190.4 (± 22.9) =.78 LDL-C 119.6 (± 16.8) 119.1 (± 24.1) =.82 TGs 107.6 (± 17.9) 156.1 (± 35.1) =.03 HDL-C 44.5 (± 8.6) 40.1 (± 7.8) =.16 AST 22.1 (± 3.3) 29.3 (± 8.5) =.42 ALT 19.1 (± 4.8) 37.8 (± 13) =.5 ALT = alanine aminotransferase; AST = aspartate aminotransferase; CI = confidence interval; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TGs = triglycerides. Figure 4. Results: Patients Meeting TG but Not LDL-C Goals at Baseline (n = 8). 200 150 100 50 0 Preintervention TC LDL-C TGs HDL-C AST ALT ALT = alanine aminotransferase; AST = aspartate aminotransferase; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TC = total cholesterol; TGs = triglycerides. (95% CI, 1.13 1.66) per 88.6 mg/dl increase in TGs. 15 The association of increased TG concentrations with increased risk of stroke has been validated in 2 other meta-analyses. 16,17 Based on these data, there is a correlation between elevated TGs and CVD; however, as Dr. Jerzy-Roch Nofer discusses in an editorial published in 2011 in Current Opinion in Lipidology, the importance of a risk factor is contingent on finding benefit with treatment. 18 Two large interventional studies, ACCORD (Action to Control Cardiovascular Risk in Diabetes trial) and FIELDS (Fenofibrate Intervention and Event Lowering in Diabetes trial), did not show a beneficial effect on cardiovascular morbidity and mortality after a clear TG reduction. 19,20 The AC- CORD and FIELDS studies suggest that although elevated TGs may be associated with elevated cardiovascular risk, no clear protective relationship exists when TGs are reduced to the goal level. Patients in this study who had gemfibrozil discontinued exhibited an increase in TG concentrations; however, the clinical significance of the change is minimal. Additionally, none of the patients in this study had a TG concentration 500 mg/dl after the intervention; only 1 of 89 had a TG 300 mg/dl. This information indicates that most of the patients who were receiving both gemfibrozil and simvastatin likely did not need medical management of their TG levels to begin with. As mentioned earlier, numerous studies did not find a direct causal relationship between the reduction of cardiovascular risk after treating TG concentrations and the NCEP ATP III goal < 150 mg/dl. There was a small yet significant increase in average ALT in the group of patients who met both LDL-C and TG goals at baseline at follow-up. The increase in ALT met criteria for statistical significance, but both values were maintained within the range of normal values (defined as 7 to 55 units/l by the Mayo Clinic). 21 Additionally, the FDA no longer recommends routine monitoring of LF tests during statin therapy in patients with no history of abnormal results. 22 The authors concluded that the change in ALT was an incidental finding and did not require further investigation. 26 FEDERAL PRACTITIONER JULY 2014

The retrospective study design and small patient population limit the external validity of the study. Additionally, the authors did not assess patient compliance with therapy before or after the intervention, which may have skewed the results. Future studies may be designed in a randomized, controlled fashion and would ideally include a broader patient population. This study provides evidence that can be used in future clinical decisions. Patients in this study may have had slightly elevated TG levels when gemfibrozil was initiated; however, all patients with a history of TG 500 mg/dl were excluded in this study. None of the patients reached the critical threshold at study follow-up despite a history of TG 150 mg/dl (but 500 mg/dl). This study provides further compelling information that practitioners should aggressively focus on reaching LDL-C and non HDL-C goals before addressing TG concentrations. CONCLUSIONS Implementation of an automatic conversion protocol in patients prescribed both simvastatin and gemfibrozil with a baseline TG 150 mg/dl did not adversely affect lipid control. Patients whose LDL-C met goal preintervention maintained their LDL-C goal at follow-up. Additionally, patients who were not meeting LDL-C goals did not have an increase in LDL-C after the intervention, although there was not a significant improvement in LDL-C either. Both groups demonstrated a statistically significant increase in TG levels after discontinuation of gemfibrozil; however, the clinical significance of the TG change was limited. The results of this study support eliminating gemfibrozil from a statin-containing regimen in patients with low TG who are prescribed the combination. Author disclosures The authors report no actual or potential conflicts of interest with regard to this article. Disclaimer The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the U.S. Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combinations including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients. REFERENCES 1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22. 2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). Lancet. 1994;344(8934):1383-1389. 3. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497. 4. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol level: A meta-analysis of population based prospective studies. J Cardiovasc Risk. 1996;3(2): 213-219. 5. Gotto AM Jr. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J. 2002;144(suppl 6):S33-S42. 6. Pedersen TR, Tobert JA. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: A reappraisal. Drug Saf. 1996;14(1):11-24. 7. Zocor [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2014. 8. Rubins HB, Robins SJ, Collins D, et al; for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341(6):410-418. 9. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237-1245. 10. Backman JT, Kyrklund C, Kivistö KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther. 2000;68(2):122-129. 11. U.S. Food and Drug Administration. FDA Drug Safety Communication: High Dose Simvastatin. U.S. Food and Drug Administration Website. http://www.fda.gov/drugs/drugsafety /ucm256581.htm. Updated January 3, 2013. Accessed June 13, 2014. 12. SEARCH Collaborative Group, Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: A double-blind, randomised trial. Lancet. 2010;376(9753):1658-1669. 13. Gaist D, Rodríguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: A population based follow-up study. Epidemiology. 2001;12(1):565-569. 14. Lindenstrøm E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: The Copenhagen City Heart Study. BMJ. 1994;309(6946):11-15. 15. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A metaanalysis of population-based prospective studies. J Cardiovasc Risk. 1996;3(2):213-219. 16. Labreuche J, Deplanque D, Touboul PJ, Bruckert E, Amarenco P. Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis: Systematic review and meta-regression analysis. Atherosclerosis. 2010;212(1):9-15. 17. De Caterina R, Scarano M, Marfisi R, et al. Cholesterol-lowering interventions and stroke: Insights from a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2010;55(3): 198-211. 18. Nofer JR. Hyperlipidemia and cardiovascular disease: Triglycerides a revival of cardiovascular risk factor? Curr Opin Lipidol. 2011;22(4): 319-321. 19. ACCORD Study Group; Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Eng J Med. 2010;362(17):1563-1574. 20. Keech A, Simes RJ, Barter P, et al; FIELD Study Investigators. Effects of long term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet. 2005;366(9500):1849-1861. 21. Mayo Clinic. Liver function tests. Mayo Clinic Website. http://www.mayoclinic.org/tests -procedures/liver-function-tests/basics/results/prc- 20012602. Accessed May 30, 2014. 22. U.S. Food and Drug Administration. FDA drug safety communication: Important safety label changes to cholesterol-lowering statin drugs. U.S. Food and Drug Administration Website. http:// www.fda.gov/drugs/drugsafety/ucm293101.htm#sa. Update July 7, 2012. Accessed May 30, 2014. JULY 2014 FEDERAL PRACTITIONER 27